Cargando…

Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gritsch, Herbert, Schrenk, Gerald, Weinhappl, Nina, Mellgård, Björn, Ewenstein, Bruce, Turecek, Peter L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673800/
https://www.ncbi.nlm.nih.gov/pubmed/36405429
http://dx.doi.org/10.2147/JBM.S377126
_version_ 1784833024860356608
author Gritsch, Herbert
Schrenk, Gerald
Weinhappl, Nina
Mellgård, Björn
Ewenstein, Bruce
Turecek, Peter L
author_facet Gritsch, Herbert
Schrenk, Gerald
Weinhappl, Nina
Mellgård, Björn
Ewenstein, Bruce
Turecek, Peter L
author_sort Gritsch, Herbert
collection PubMed
description BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme. PURPOSE: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P(®)/Humate-P(®), Voncento(®), Wilate(®)/Eqwilate(®), and Wilfactin(®)/Willfact(®); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF. METHODS: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed. RESULTS: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P(®), Voncento(®) and Wilate(®). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation. CONCLUSIONS: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy.
format Online
Article
Text
id pubmed-9673800
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96738002022-11-19 Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease Gritsch, Herbert Schrenk, Gerald Weinhappl, Nina Mellgård, Björn Ewenstein, Bruce Turecek, Peter L J Blood Med Original Research BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme. PURPOSE: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P(®)/Humate-P(®), Voncento(®), Wilate(®)/Eqwilate(®), and Wilfactin(®)/Willfact(®); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF. METHODS: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed. RESULTS: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P(®), Voncento(®) and Wilate(®). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation. CONCLUSIONS: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy. Dove 2022-11-14 /pmc/articles/PMC9673800/ /pubmed/36405429 http://dx.doi.org/10.2147/JBM.S377126 Text en © 2022 Gritsch et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gritsch, Herbert
Schrenk, Gerald
Weinhappl, Nina
Mellgård, Björn
Ewenstein, Bruce
Turecek, Peter L
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title_full Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title_fullStr Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title_full_unstemmed Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title_short Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
title_sort structure and function of recombinant versus plasma-derived von willebrand factor and impact on multimer pharmacokinetics in von willebrand disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673800/
https://www.ncbi.nlm.nih.gov/pubmed/36405429
http://dx.doi.org/10.2147/JBM.S377126
work_keys_str_mv AT gritschherbert structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease
AT schrenkgerald structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease
AT weinhapplnina structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease
AT mellgardbjorn structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease
AT ewensteinbruce structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease
AT turecekpeterl structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease